APA (7th ed.) Citation

Nasca, V., Bergamo, F., Foltran, L., Antonuzzo, L., Bencardino, K., Dell'Aquila, E., . . . Morano, F. (2025). Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: The multicentre, phase II randomized TRINITY trial. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-025-14063-6

Chicago Style (17th ed.) Citation

Nasca, Vincenzo, et al. "Adjuvant TRastuzumab Deruxtecan Plus Fluoropyrimidine Versus Standard Chemotherapy in HER2-positive Gastric or Gastroesophageal Cancer Patients with Persistence of Minimal Residual Disease in Liquid Biopsy After Pre-operative Chemotherapy and Radical Surgery: The Multicentre, Phase II Randomized TRINITY Trial." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-025-14063-6.

MLA (9th ed.) Citation

Nasca, Vincenzo, et al. "Adjuvant TRastuzumab Deruxtecan Plus Fluoropyrimidine Versus Standard Chemotherapy in HER2-positive Gastric or Gastroesophageal Cancer Patients with Persistence of Minimal Residual Disease in Liquid Biopsy After Pre-operative Chemotherapy and Radical Surgery: The Multicentre, Phase II Randomized TRINITY Trial." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-025-14063-6.